JAK1

(redirected from Janus kinase 1)
Also found in: Wikipedia.

JAK1

A gene on chromosome 1p32.3-p31.3 that encodes a non-receptor protein tyrosine kinase involved in the IFN-alpha/beta/gamma signal pathway, which is further characterised by a second phosphotransferase-related domain immediately N-terminal to the PTK domain.
References in periodicals archive ?
Pfizer announced its once-daily oral Janus kinase 1 inhibitor PF-04965842 received Breakthrough Therapy designation from the U.
The way has already been paved for dermatologic researchers by veterinarians, who developed oclacitinib (Apoquel), a relatively selective Janus kinase 1 (JAKl) inhibitor, for canine AD.
NYSE: PFE) has initiated a Phase 3 program to evaluate the efficacy and safety of its once-daily Janus kinase 1 inhibitor, PF-04965842, for the treatment of moderate-to-severe atopic dermatitis (AD), the company said.
Pfizer Inc today announced the initiation of a Phase 3 program for its once-daily Janus kinase 1 (JAK1) inhibitor PF-04965842, to evaluate the efficacy and safety of PF-04965842 for the treatment of moderate-to-severe atopic dermatitis (AD).
An opportunistic infection associated with ruxolitinib, a novel janus kinase 1, 2 inhibitor.
GSK2586184 is a Janus kinase 1 (JAK1) inhibitor, which is developed within Galapagos's inflammation alliance withA GSK.
Biotechnology company Galapagos NV (Euronext:GLPG) (OTC:GLPYY) announced today that it has started its second Phase IIa clinical study with GLPG0634, a novel Janus kinase 1 (JAK1) inhibitor being developed to treat multiple autoimmune diseases, such as rheumatoid arthritis (RA).
GLPG0634 is a novel Janus kinase 1 (JAK1) inhibitor which is being developed to treat multiple autoimmune diseases, including rheumatoid arthritis (RA).
22 November 2011 - Belgian biotechnology company Galapagos NV (EBR:GLPG) said today that its Janus kinase 1 (JAK1) inhibitor, GLPG0634, had achieved the primary endpoint of significant improvement in the signs and symptoms of rheumatoid arthritis (RA).